Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    DPDr. Daniel Pollyea
    Leading Voice

    Dr. Daniel Pollyea

    Hematology & Oncology · Leukemia
    University of Colorado Anschutz
    danielpollyea
    Denver, CO, USA

    Research

    Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine

    2026

    Via Am J Hematol

    Research

    Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies

    2026

    Via Am J Hematol

    Research

    Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

    2026

    Via Am J Hematol

    Research

    Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

    2026

    Via Haematologica

    Research

    NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026

    2026

    Via J Natl Compr Canc Netw

    Research

    Weakened macrophage antibacterial capacity in myelodysplastic syndrome

    2026

    Via Immunohorizons

    Research

    Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study

    2026

    Via Leuk Lymphoma

    Research

    Myeloid differentiation-associated autophagy drives venetoclax resistance in AML

    2026

    Via Res Sq

    Research

    Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

    2026

    Via Haematologica

    Research

    Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

    2026

    Via J Clin Oncol

    Research

    RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma

    2026

    Via Blood Cancer Discov

    Research

    The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells

    2026

    Via Blood Cancer Discov

    Research

    A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia

    2026

    Via Blood Adv

    Research

    Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic Leukemia

    2026

    Via Eur J Haematol

    Research

    Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma

    2025

    Via bioRxiv